The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene.
* Aged between 18 and 80 years at inclusion.
Exclusion Criteria:
* Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP)
* (Chronic) Inflammatory bowel disease
* Non-Dutch speaking
* Dementia or another mental condition that makes it impossible to fill out questionnaires
* Terminally ill persons
Primary outcome measure(s)
Colorectal tumour diagnoses — Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports. All diagnosed colorectal adenomas and carcinomas described in paticipants' medical reports and/or pathology reports.
Endometrial cancer diagnoses — Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports. All diagnosed endometrial cancers described in participants' medical reports and/or pathology reports.
Overall cancer diagnoses — Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports. All diagnosed cancer types described in participants' medical reports and/or pathology reports.
Trial sites (1)
Facility
City
Region
Status
Wageningen University
Wageningen
Netherlands
Recruiting
More Wageningen University trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.